Caris Life Sciences uses a variety of technology platforms to conduct pre-clinical research with biopharma partners, including Next Generation Sequencing, Mass Spectrometry and our proprietary ADAPT Biotargeting System, a unique and powerful platform for biomarker and drug target discovery.

  • Leverage enriched binding agents for multiplexed affinity capture and target/biomarker discovery
  • Uncover novel molecular complexes, epitopes, neoantigens and mechanisms of action
  • Identify unique biomarkers of interest including proteins, miRNAs, molecular complexes and polyligand signatures
  • Reveal low abundance targets and eliminate uninformative biological noise

Discover important biological information utilizing a variety of sample types:

  • Formalin-fixed paraffin-embedded (FFPE), fresh and frozen tissue
  • Cell lines, primary cells and conditioned media
  • Exosomes and other microvesicles
  • Whole blood, plasma or serum; bone marrow
  • Cerebrospinal fluid; malignant fluid
  • Urine